+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Metabolic Disorder Therapeutics Market Size, Share & Trends Analysis Report By Disease, By Therapy, By Route Of Administration (Oral, Parenteral), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • PDF Icon

    Report

  • 100 Pages
  • November 2024
  • Region: Global
  • Grand View Research
  • ID: 6032527
The global metabolic disorder therapeutics market size is expected to reach USD 120.71 billion by 2030, registering a CAGR of 7.8% from 2025 to 2030. Rising incidences of diabetes, obesity, and hypercholesterolemia are expected to drive the market growth. It is estimated that by 2040, about 1 person in 11 people worldwide is likely to suffer from one of the aforementioned diseases.

Researchers estimate that the prevalence of metabolic diseases like obesity and diabetes is expected to double in the coming 2 decades, mainly in U.S. and Asian and Latin American countries. This, in turn, will help boost the overall market growth in the year to come. Furthermore, with better economic stability in developing countries, demand for novel therapeutics for one-time treatment has increased. This has made major companies in the global market to invest heavily in R&D to develop innovative therapy options. All these factors will contribute to the development of the market.

Metabolic Disorder Therapeutics Market Report Highlights

  • Diabetes dominated the market and accounted for a share of 29.8% in 2024, driven by the increasing prevalence of diabetes, particularly type 2 diabetes, affecting more than 5% of the global population.
  • Lysosomal storage diseases (LSDs) are expected to grow at the fastest CAGR of 9.3% over the forecast period. LSDs are progressive neurological conditions resulting from enzyme deficiencies, causing severe symptoms and early mortality.
  • Enzyme replacement therapy (ERT) led the market with a revenue share of 30.6% in 2024. ERT targets the fundamental enzyme deficiencies associated with lysosomal storage disorders, significantly improving patient health and quality of life.
  • Gene therapy is anticipated to witness the fastest rate of 9.7% over the forecast period. Gene therapy holds significant potential to offer curative solutions for inherited metabolic diseases with limited treatment options.
  • Parenteral therapeutics held the largest market share of 50.0% in 2024, aided by rapid onset of action and high bioavailability. Parenteral administration effectively bypasses the gastrointestinal tract, avoiding first-pass metabolism, crucial for immediate therapeutic effects.
  • Oral therapeutics are expected to register the fastest CAGR of 8.2% over the forecast period. Oral administration is non-invasive, easy for patients to self-administer, and typically preferred over injections, resulting in higher treatment adherence.
  • Hospital pharmacies dominated the market with a revenue share of 44.6% in 2024. Hospital pharmacies play a vital role in dispensing complex medications, particularly for metabolic disorders that necessitate specialized handling.
  • North America metabolic disorder therapeutics market dominated the global market with a revenue share of 39.9% in 2024. North America boasts a strong healthcare infrastructure, substantial investments in research and development, and a notable prevalence of metabolic disorders such as diabetes and obesity.

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Disease
1.2.2. Therapy
1.2.3. Route of Administration
1.2.4. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Metabolic Disorder Therapeutics Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
Chapter 4. Metabolic Disorder Therapeutics Market: Disease Business Analysis
4.1. Disease Market Share, 2024 & 2030
4.2. Disease Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Disease, 2018 to 2030 (USD Million)
4.4. Lysosomal Storage Diseases
4.4.1. Lysosomal Storage Diseases Market, 2018 - 2030 (USD Million)
4.5. Diabetes
4.5.1. Diabetes Market, 2018 - 2030 (USD Million)
4.6. Obesity
4.6.1. Obesity Market, 2018 - 2030 (USD Million)
4.7. Inherited Metabolic Disorders
4.7.1. Inherited Metabolic Disorders Market, 2018 - 2030 (USD Million)
4.8. Hypercholesterolemia
4.8.1. Hypercholesterolemia Market, 2018 - 2030 (USD Million)
4.9. Other Metabolic Diseases
4.9.1. Other Metabolic Diseases Market, 2018 - 2030 (USD Million)
Chapter 5. Metabolic Disorder Therapeutics Market: Therapy Business Analysis
5.1. Therapy Market Share, 2024 & 2030
5.2. Therapy Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Therapy, 2018 to 2030 (USD Million)
5.4. Enzyme Replacement Therapy
5.4.1. Enzyme Replacement Therapy Market, 2018 - 2030 (USD Million)
5.5. Cellular Transplantation
5.5.1. Cellular Transplantation Market, 2018 - 2030 (USD Million)
5.6. Small Molecule Based Therapy
5.6.1. Small Molecule Based Therapy Market, 2018 - 2030 (USD Million)
5.7. Substrate Reduction Therapy
5.7.1. Substrate Reduction Therapy Market, 2018 - 2030 (USD Million)
5.8. Gene Therapy
5.8.1. Gene Therapy Market, 2018 - 2030 (USD Million)
5.9. Drug Therapy
5.9.1. Drug Therapy Market, 2018 - 2030 (USD Million)
Chapter 6. Metabolic Disorder Therapeutics Market: Route of Administration Business Analysis
6.1. Route of Administration Market Share, 2024 & 2030
6.2. Route of Administration Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
6.4. Oral
6.4.1. Oral Market, 2018 - 2030 (USD Million)
6.5. Parenteral
6.5.1. Parenteral Market, 2018 - 2030 (USD Million)
6.6. Others
6.6.1. Others Market, 2018 - 2030 (USD Million)
Chapter 7. Metabolic Disorder Therapeutics Market: Distribution Channel Business Analysis
7.1. Distribution Channel Market Share, 2024 & 2030
7.2. Distribution Channel Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
7.4. Hospital Pharmacies
7.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
7.5. Retail Pharmacies
7.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
7.6. Online Pharmacies
7.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)
Chapter 8. Metabolic Disorder Therapeutics Market: Regional Estimates & Trend Analysis by Disease, Therapy, Route of Administration, and Distribution Channel
8.1. Regional Market Share Analysis, 2024 & 2030
8.2. Regional Market Dashboard
8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
8.4. North America
8.4.1. North America Metabolic Disorder Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
8.4.2. U.S.
8.4.2.1. Key Country Dynamics
8.4.2.2. Regulatory Framework
8.4.2.3. Competitive Insights
8.4.2.4. U.S. Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.4.3. Canada
8.4.3.1. Key Country Dynamics
8.4.3.2. Regulatory Framework
8.4.3.3. Competitive Insights
8.4.3.4. Canada Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.4.4. Mexico
8.4.4.1. Key Country Dynamics
8.4.4.2. Regulatory Framework
8.4.4.3. Competitive Insights
8.4.4.4. Mexico Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5. Europe
8.5.1. Europe Metabolic Disorder Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
8.5.2. UK
8.5.2.1. Key Country Dynamics
8.5.2.2. Regulatory Framework
8.5.2.3. Competitive Insights
8.5.2.4. UK Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.3. Germany
8.5.3.1. Key Country Dynamics
8.5.3.2. Regulatory Framework
8.5.3.3. Competitive Insights
8.5.3.4. Germany Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.4. France
8.5.4.1. Key Country Dynamics
8.5.4.2. Regulatory Framework
8.5.4.3. Competitive Insights
8.5.4.4. France Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.5. Italy
8.5.5.1. Key Country Dynamics
8.5.5.2. Regulatory Framework
8.5.5.3. Competitive Insights
8.5.5.4. Italy Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.6. Spain
8.5.6.1. Key Country Dynamics
8.5.6.2. Regulatory Framework
8.5.6.3. Competitive Insights
8.5.6.4. Spain Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.7. Norway
8.5.7.1. Key Country Dynamics
8.5.7.2. Regulatory Framework
8.5.7.3. Competitive Insights
8.5.7.4. Norway Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.8. Denmark
8.5.8.1. Key Country Dynamics
8.5.8.2. Regulatory Framework
8.5.8.3. Competitive Insights
8.5.8.4. Denmark Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.9. Sweden
8.5.9.1. Key Country Dynamics
8.5.9.2. Regulatory Framework
8.5.9.3. Competitive Insights
8.5.9.4. Sweden Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6. Asia Pacific
8.6.1. Asia Pacific Metabolic Disorder Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
8.6.2. Japan
8.6.2.1. Key Country Dynamics
8.6.2.2. Regulatory Framework
8.6.2.3. Competitive Insights
8.6.2.4. Japan Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6.3. China
8.6.3.1. Key Country Dynamics
8.6.3.2. Regulatory Framework
8.6.3.3. Competitive Insights
8.6.3.4. China Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6.4. India
8.6.4.1. Key Country Dynamics
8.6.4.2. Regulatory Framework
8.6.4.3. Competitive Insights
8.6.4.4. India Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6.5. South Korea
8.6.5.1. Key Country Dynamics
8.6.5.2. Regulatory Framework
8.6.5.3. Competitive Insights
8.6.5.4. South Korea Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6.6. Australia
8.6.6.1. Key Country Dynamics
8.6.6.2. Regulatory Framework
8.6.6.3. Competitive Insights
8.6.6.4. Australia Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6.7. Thailand
8.6.7.1. Key Country Dynamics
8.6.7.2. Regulatory Framework
8.6.7.3. Competitive Insights
8.6.7.4. Thailand Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.7. Latin America
8.7.1. Latin America Metabolic Disorder Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
8.7.2. Brazil
8.7.2.1. Key Country Dynamics
8.7.2.2. Regulatory Framework
8.7.2.3. Competitive Insights
8.7.2.4. Brazil Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.7.3. Argentina
8.7.3.1. Key Country Dynamics
8.7.3.2. Regulatory Framework
8.7.3.3. Competitive Insights
8.7.3.4. Argentina Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.8. MEA
8.8.1. MEA Metabolic Disorder Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
8.8.2. South Africa
8.8.2.1. Key Country Dynamics
8.8.2.2. Regulatory Framework
8.8.2.3. Competitive Insights
8.8.2.4. South Africa Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.8.3. Saudi Arabia
8.8.3.1. Key Country Dynamics
8.8.3.2. Regulatory Framework
8.8.3.3. Competitive Insights
8.8.3.4. Saudi Arabia Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.8.4. UAE
8.8.4.1. Key Country Dynamics
8.8.4.2. Regulatory Framework
8.8.4.3. Competitive Insights
8.8.4.4. UAE Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.8.5. Kuwait
8.8.5.1. Key Country Dynamics
8.8.5.2. Regulatory Framework
8.8.5.3. Competitive Insights
8.8.5.4. Kuwait Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Participant Overview
9.2. Company Market Position Analysis
9.3. Company Categorization
9.4. Strategy Mapping
9.5. Company Profiles/Listing
9.5.1. Novo Nordisk A/S
9.5.1.1. Overview
9.5.1.2. Financial Performance
9.5.1.3. Product Benchmarking
9.5.1.4. Strategic Initiatives
9.5.2. Eli Lilly and Company
9.5.2.1. Overview
9.5.2.2. Financial Performance
9.5.2.3. Product Benchmarking
9.5.2.4. Strategic Initiatives
9.5.3. Takeda Pharmaceutical Company Limited
9.5.3.1. Overview
9.5.3.2. Financial Performance
9.5.3.3. Product Benchmarking
9.5.3.4. Strategic Initiatives
9.5.4. Sanofi
9.5.4.1. Overview
9.5.4.2. Financial Performance
9.5.4.3. Product Benchmarking
9.5.4.4. Strategic Initiatives
9.5.5. Merck KGaA
9.5.5.1. Overview
9.5.5.2. Financial Performance
9.5.5.3. Product Benchmarking
9.5.5.4. Strategic Initiatives
9.5.6. AstraZeneca
9.5.6.1. Overview
9.5.6.2. Financial Performance
9.5.6.3. Product Benchmarking
9.5.6.4. Strategic Initiatives
9.5.7. AbbVie Inc.
9.5.7.1. Overview
9.5.7.2. Financial Performance
9.5.7.3. Product Benchmarking
9.5.7.4. Strategic Initiatives
9.5.8. Johnson & Johnson Innovative Medicine
9.5.8.1. Overview
9.5.8.2. Financial Performance
9.5.8.3. Product Benchmarking
9.5.8.4. Strategic Initiatives
9.5.9. Amgen Inc.
9.5.9.1. Overview
9.5.9.2. Financial Performance
9.5.9.3. Product Benchmarking
9.5.9.4. Strategic Initiatives
9.5.10. Biocon
9.5.10.1. Overview
9.5.10.2. Financial Performance
9.5.10.3. Product Benchmarking
9.5.10.4. Strategic Initiatives
9.5.11. BioMarin
9.5.11.1. Overview
9.5.11.2. Financial Performance
9.5.11.3. Product Benchmarking
9.5.11.4. Strategic Initiatives
9.5.12. Boehringer Ingelheim International GmbH
9.5.12.1. Overview
9.5.12.2. Financial Performance
9.5.12.3. Product Benchmarking
9.5.12.4. Strategic Initiatives
9.5.13. Bristol-Myers Squibb Company
9.5.13.1. Overview
9.5.13.2. Financial Performance
9.5.13.3. Product Benchmarking
9.5.13.4. Strategic Initiatives
9.5.14. Cipla Inc.
9.5.14.1. Overview
9.5.14.2. Financial Performance
9.5.14.3. Product Benchmarking
9.5.14.4. Strategic Initiatives
List of Tables
Table 1. List of secondary sources
Table 2. List of abbreviations
Table 3. Global metabolic disorder therapeutics market, by region, 2018 - 2030 (USD Million)
Table 4. Global metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 5. Global metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
Table 6. Global metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 7. Global metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 8. North America metabolic disorder therapeutics market, by country, 2018 - 2030 (USD Million)
Table 9. North America metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 10. North America metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
Table 11. North America metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 12. North America metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 13. U.S. metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 14. U.S. metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
Table 15. U.S. metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 16. U.S. metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 17. Canada metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 18. Canada metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
Table 19. Canada metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 20. Canada metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 21. Mexico metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 22. Mexico metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
Table 23. Mexico metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 24. Mexico metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 25. Europe metabolic disorder therapeutics market, by country, 2018 - 2030 (USD Million)
Table 26. Europe metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 27. Europe metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
Table 28. Europe metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 29. Europe metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 30. UK metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 31. UK metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
Table 32. UK metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 33. UK metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 34. Germany metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 35. Germany metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
Table 36. Germany metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 37. Germany metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 38. France metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 39. France metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
Table 40. France metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 41. France metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 42. Italy metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 43. Italy metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
Table 44. Italy metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 45. Italy metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 46. Spain metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 47. Spain metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
Table 48. Spain metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 49. Spain metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 50. Denmark metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 51. Denmark metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
Table 52. Denmark metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 53. Denmark metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 54. Sweden metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 55. Sweden metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
Table 56. Sweden metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 57. Sweden metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 58. Norway metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 59. Norway metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
Table 60. Norway metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 61. Norway metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 62. Asia Pacific metabolic disorder therapeutics market, by country, 2018 - 2030 (USD Million)
Table 63. Asia Pacific metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 64. Asia Pacific metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
Table 65. Asia Pacific metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 66. Asia Pacific metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 67. China metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 68. China metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
Table 69. China metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 70. China metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 71. Japan metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 72. Japan metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
Table 73. Japan metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 74. Japan metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 75. India metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 76. India metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
Table 77. India metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 78. India metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 79. Australia metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 80. Australia metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
Table 81. Australia metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 82. Australia metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 83. South Korea metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 84. South Korea metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
Table 85. South Korea metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 86. South Korea metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 87. Thailand metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 88. Thailand metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
Table 89. Thailand metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 90. Thailand metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 91. Latin America metabolic disorder therapeutics market, by country, 2018 - 2030 (USD Million)
Table 92. Latin America metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 93. Latin America metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
Table 94. Latin America metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 95. Latin America metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 96. Brazil metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 97. Brazil metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
Table 98. Brazil metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 99. Brazil metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 100. Argentina metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 101. Argentina metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
Table 102. Argentina metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 103. Argentina metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 104. Middle East & Africa Metabolic disorder therapeutics market, by country, 2018 - 2030 (USD Million)
Table 105. Middle East & Africa metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 106. Middle East & Africa metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
Table 107. Middle East & Africa metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 108. Middle East & Africa metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 109. South Africa metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 110. South Africa metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
Table 111. South Africa metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 112. South Africa metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 113. Saudi Arabia metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 114. Saudi Arabia metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
Table 115. Saudi Arabia metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 116. Saudi Arabia metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 117. UAE metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 118. UAE metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
Table 119. UAE metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 120. UAE metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
Table 121. Kuwait metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
Table 122. Kuwait metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
Table 123. Kuwait metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
Table 124. Kuwait metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Metabolic disorder therapeutics market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Disease and therapy outlook (USD Million)
Fig. 10 Route of administration and distribution channel outlook (USD Million)
Fig. 11 Competitive landscape
Fig. 12 Metabolic disorder therapeutics market dynamics
Fig. 13 Metabolic disorder therapeutics market: Porter’s five forces analysis
Fig. 14 Metabolic disorder therapeutics market: PESTLE analysis
Fig. 15 Metabolic disorder therapeutics market: Disease segment dashboard
Fig. 16 Metabolic disorder therapeutics market: Disease market share analysis, 2024 & 2030
Fig. 17 Lysosomal storage diseases market, 2018 - 2030 (USD Million)
Fig. 18 Diabetes market, 2018 - 2030 (USD Million)
Fig. 19 Obesity market, 2018 - 2030 (USD Million)
Fig. 20 Inherited metabolic disorders market, 2018 - 2030 (USD Million)
Fig. 21 Hypercholesterolemia market, 2018 - 2030 (USD Million)
Fig. 22 Other metabolic diseases market, 2018 - 2030 (USD Million)
Fig. 23 Metabolic disorder therapeutics market: Therapy segment dashboard
Fig. 24 Metabolic disorder therapeutics market: Therapy market share analysis, 2024 & 2030
Fig. 25 Enzyme replacement therapy market, 2018 - 2030 (USD Million)
Fig. 26 Cellular transplantation market, 2018 - 2030 (USD Million)
Fig. 27 Small molecule based therapy market, 2018 - 2030 (USD Million)
Fig. 28 Substrate reduction therapy market, 2018 - 2030 (USD Million)
Fig. 29 Gene therapy market, 2018 - 2030 (USD Million)
Fig. 30 Drug therapy market, 2018 - 2030 (USD Million)
Fig. 31 Metabolic disorder therapeutics market: Route of administration segment dashboard
Fig. 32 Metabolic disorder therapeutics market: Route of administration market share analysis, 2024 & 2030
Fig. 33 Oral market, 2018 - 2030 (USD Million)
Fig. 34 Parenteral market, 2018 - 2030 (USD Million)
Fig. 35 Others market, 2018 - 2030 (USD Million)
Fig. 36 Metabolic disorder therapeutics market: Distribution channel segment dashboard
Fig. 37 Metabolic disorder therapeutics market: Distribution channel market share analysis, 2024 & 2030
Fig. 38 Hospital pharmacies market, 2018 - 2030 (USD Million)
Fig. 39 Retail pharmacies market, 2018 - 2030 (USD Million)
Fig. 40 Online pharmacies market, 2018 - 2030 (USD Million)
Fig. 41 Metabolic disorder therapeutics market revenue, by region
Fig. 42 Regional marketplace: Key takeaways
Fig. 43 Regional marketplace: Key takeaways
Fig. 44 North America metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
Fig. 45 U.S. country dynamics
Fig. 46 U.S. metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
Fig. 47 Canada country dynamics
Fig. 48 Canada metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
Fig. 49 Mexico country dynamics
Fig. 50 Mexico metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
Fig. 51 Europe metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
Fig. 52 UK country dynamics
Fig. 53 UK metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
Fig. 54 Germany country dynamics
Fig. 55 Germany metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
Fig. 56 France country dynamics
Fig. 57 France metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
Fig. 58 Italy country dynamics
Fig. 59 Italy metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
Fig. 60 Spain country dynamics
Fig. 61 Spain metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
Fig. 62 Norway country dynamics
Fig. 63 Norway metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
Fig. 64 Sweden country dynamics
Fig. 65 Sweden metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
Fig. 66 Denmark country dynamics
Fig. 67 Denmark metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
Fig. 68 Asia Pacific metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
Fig. 69 Japan country dynamics
Fig. 70 Japan metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
Fig. 71 China country dynamics
Fig. 72 China metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
Fig. 73 India country dynamics
Fig. 74 India metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
Fig. 75 Australia country dynamics
Fig. 76 Australia metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
Fig. 77 South Korea country dynamics
Fig. 78 South Korea metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
Fig. 79 Thailand country dynamics
Fig. 80 Thailand metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
Fig. 81 Latin America metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
Fig. 82 Brazil country dynamics
Fig. 83 Brazil metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
Fig. 84 Argentina country dynamics
Fig. 85 Argentina metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
Fig. 86 MEA metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
Fig. 87 South Africa country dynamics
Fig. 88 South Africa metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
Fig. 89 Saudi Arabia country dynamics
Fig. 90 Saudi Arabia metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
Fig. 91 UAE country dynamics
Fig. 92 UAE metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
Fig. 93 Kuwait country dynamics
Fig. 94 Kuwait metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
Fig. 95 Company categorization
Fig. 96 Company market position analysis
Fig. 97 Strategic framework

Companies Mentioned

  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Takeda Pharmaceutical Company Limited
  • Sanofi
  • Merck KGaA
  • AstraZeneca
  • AbbVie Inc.
  • Johnson & Johnson Innovative Medicine
  • Amgen Inc.
  • Biocon
  • BioMarin
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Inc.

Methodology

Loading
LOADING...

Table Information